SEHK:1818
SEHK:1818Metals and Mining

What Zhaojin Mining Industry (SEHK:1818)'s Blockchain and AI Collaboration Means For Shareholders

Zhaojin Mining Industry Co. recently announced a collaboration with Ant Digital Technologies, a division of Ant Group, to use blockchain and AI for digitizing overseas gold assets, improving supply chain oversight, and advancing sustainability. This partnership supports China's digital economic initiatives and showcases the growing role of advanced technology in the global gold sector. We'll explore how applying blockchain and AI in gold asset digitization could influence Zhaojin Mining...
SEHK:2367
SEHK:2367Personal Products

Asian Market Value Stock Picks For Potential Capital Appreciation

As the Asian markets navigate a landscape marked by mixed performances and economic shifts, investors are closely watching for opportunities amid easing U.S.-China trade tensions and Japan's record stock market highs. In this context, identifying undervalued stocks with strong fundamentals can offer potential for capital appreciation, especially as regional economies adapt to evolving global conditions.
SEHK:2333
SEHK:2333Auto

How Investors May Respond To Great Wall Motor (SEHK:2333) Expanding Dual Inverter Partnership With BorgWarner

On October 30, 2025, BorgWarner announced it will expand its partnership with Great Wall Motor by launching two additional electrified propulsion projects utilizing advanced dual inverter technology, with mass production targeted for 2026. This collaboration provides Great Wall Motor with greater flexibility and efficiency in hybrid and plug-in hybrid development, supporting regulatory compliance and quicker product iterations for the competitive Chinese automotive market. We'll explore how...
SEHK:2162
SEHK:2162Biotechs

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Goldman Sachs recently initiated coverage on Keymed Biosciences, highlighting the approval of its first commercial product, stapokibart, in China for atopic dermatitis and chronic rhinosinusitis, while expressing confidence in the pipeline asset CM512 for asthma and COPD. This development underscores the growing recognition of Keymed's product pipeline and the confidence major institutions are placing in the company's future prospects. We'll explore how optimism for Keymed's pipeline,...